2-(4-溴苯氧基)丙酰胺 | 360791-98-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(4-溴苯氧基)丙酰胺
• 英文名称: 2-(4-bromophenoxy)propanamide
• CAS: 360791-98-6
• 化学式: C₉H₁₀BrNO₂
• mdl: MFCD04219739
• 分子量: 244.088
• InChiKey: GBEDJWZQBGSKBM-UHFFFAOYSA-N

物化性质

• 沸点：
  393.3±22.0 °C(Predicted)
• 密度：
  1.490±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-溴苯氧基)丙酰胺 在 potassium hydroxide 作用下， 以126.5 mg的产率得到4-溴苯胺
  参考文献：
  名称：

  无金属条件下苯酚的直接胺化

  摘要：

  在此，我们公开了通过使用胺化试剂直接胺化苯酚来无金属合成芳胺。该反应过程使用容易获得的胺化试剂，并为具有各种官能度的广泛芳胺提供了一种通用的合成途径，收率良好至极好。通过使用胺化和氧化偶联反应的两步路线，我们从两种市售酚类合成了三种天然存在的咔唑生物碱：murrayafoline A、mukonine 和黄花碱。

  DOI：

  10.1055/s-0033-1338703
• 作为产物：
  描述：

  2-(4-溴苯氧基)丙酸甲酯 在 氨 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 48.0h， 以100%的产率得到2-(4-溴苯氧基)丙酰胺
  参考文献：
  名称：

  Sulfonamide derivatives

  摘要：

  本发明提供了一些磺胺衍生物，可用于增强患者的谷氨酸受体功能，因此可用于治疗多种疾病，如精神疾病和神经系统疾病。

  公开号：

  US20030225266A1

文献信息

• [EN] [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS [1,2,4]TRIAZOLO[1,5-A]PYRIDINE ET [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009047514A1

  公开（公告）日：2009-04-16

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明一般涉及治疗化合物领域，更具体地涉及某些三唑化合物（以下简称为TAZ化合物），特别是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，这些化合物等等，可以抑制AXL受体酪氨酸激酶功能。本发明还涉及包括这些化合物的药物组合物，以及使用这些化合物和组合物，无论是体外还是体内，来抑制AXL受体酪氨酸激酶功能，并用于治疗由AXL受体酪氨酸激酶介导的疾病和病况，通过抑制AXL受体酪氨酸激酶功能得到缓解的疾病和病况等，包括增生性疾病如癌症等。
• [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use
  申请人：Cancer Research Technology Limited

  公开号：US20140155594A1

  公开（公告）日：2014-06-05

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明涉及治疗化合物领域，更具体地涉及某些三唑化合物（在此称为TAZ化合物），特别是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，其中包括抑制AXL受体酪氨酸激酶功能的化合物。本发明还涉及包括这些化合物的制药组合物，以及使用这些化合物和组合物在体内外抑制AXL受体酪氨酸激酶功能，并用于治疗由AXL受体酪氨酸激酶介导的疾病和病症，通过抑制AXL受体酪氨酸激酶功能得到缓解的疾病和病症，包括增生性疾病如癌症等。
• [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use
  申请人：Pavé Grégoire Alexandre

  公开号：US08431596B2

  公开（公告）日：2013-04-30

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明一般涉及治疗化合物领域，更具体地涉及某些三唑化合物（以下简称TAZ化合物），尤其是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，它们可以抑制AXL受体酪氨酸激酶功能。本发明还涉及包含这种化合物的制药组合物，并且在体内外使用这种化合物和组合物来抑制AXL受体酪氨酸激酶功能，治疗由AXL受体酪氨酸激酶介导的疾病和病状，通过抑制AXL受体酪氨酸激酶功能改善这些疾病和病状，包括增生性疾病如癌症等。
• FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES
  申请人：Braun Christoph

  公开号：US20140349848A1

  公开（公告）日：2014-11-27

  The present invention provides fungicidal 4-substituted-3-phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadiazol-5(4H)-one derivatives of formula (I) wherein A represents a pyridyl or thiazole group and X1, Y1 to Y5 represent independently different substituents.

  本发明提供了式（I）的杀真菌4-取代-3- 苯基 [（杂环甲氧基）亚胺]甲基} -1,2,4-噁唑-5（4H）-酮衍生物，其中A代表吡啶基或噻唑基，X1，Y1至Y5分别代表不同的取代基。
• Metal-free C–N bond-forming reaction: straightforward synthesis of anilines, through cleavage of aryl C–O bond and amide C–N bond
  作者：Jianzhong Yu、Peizhi Zhang、Jun Wu、Zhicai Shang

  DOI：10.1016/j.tetlet.2013.04.028

  日期：2013.6

  An efficient metal-free C-N bond forming reaction through cleavage of aryl C-O bond and amide C-N bond has been developed. This process represents a practical method for the facile construction of anilines with a broad substrate scope and wide functional group tolerance in moderate to excellent yields. (C) 2013 Elsevier Ltd. All rights reserved.